Psoriatic arthritis: current therapy and future approaches

Huynh, DoQuyen; Kavanaugh, Arthur

doi:10.1093/rheumatology/keu237

Cited by 61 publications

(66 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Emotional issues were often linked to concepts in other categories, such as pain or itching. For example, one patient 3 …”

Section: Data Source and Patient Populationmentioning

confidence: 99%

“…About 30% of patients with psoriasis will develop psoriatic arthritis (PsA), a chronic, inflammatory disease affecting the musculoskeletal system 2,3 . PsA may present with ≥ 1 clinical subtype, including peripheral joint inflammation, enthesitis, dactylitis, axial spondylitis, and varying severity of nail and skin changes; the heterogeneous aspect of this disease makes diagnosis and treatment challenging 4,5 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Sunkureddi

Doogan²,

Heid³

et al. 2018

J Rheumatol

View full text Add to dashboard Cite

Objective.To evaluate the types of experiences and treatment access challenges of patients with psoriatic arthritis (PsA) using self-reported online narratives.Methods.English-language patient narratives reported between January 2010 and May 2016 were collected from 31 online sources (general health social networking sites, disease-focused patient forums, treatment reviews, general health forums, mainstream social media sites) for analysis of functional impairment and 40 online sources for assessment of barriers to treatment. Using natural language processing and manual curation, patient-reported experiences were categorized into 6 high-level concepts of functional impairment [social, physical, emotional, cognitive, role activity (SPEC-R), and general] and 6 categories to determine barriers to treatment access (coverage ineligibility, out-of-pocket cost, issues with assistance programs, clinical ineligibility, formulary placement/sequence, doctor guidance). The SPEC-R categorization was also applied to 3 validated PsA patient-reported outcome (PRO) instruments to evaluate their capacity to collect lower-level subconcepts extracted from patient narratives.Results.Of 15,390 narratives collected from 3139 patients with PsA for exploratory analysis, physical concepts were the most common (81.5%), followed by emotional (50.7%), cognitive (20.0%), role activity (8.1%), and social (5.6%) concepts. Cognitive impairments and disease burden on family and parenting were not recorded by PsA PRO instruments. The most commonly cited barriers to treatment were coverage ineligibility (51.6%) and high out-of-pocket expenses (31.7%).Conclusion.Patients often discussed physical and emotional implications of PsA in online platforms; some commonly used PRO instruments in PsA may not identify cognitive issues or parenting/family burden. Nearly one-third of patients with PsA reported access barriers to treatment.

show abstract

“…Emotional issues were often linked to concepts in other categories, such as pain or itching. For example, one patient 3 …”

Section: Data Source and Patient Populationmentioning

confidence: 99%

mentioning

confidence: 99%

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Sunkureddi

Doogan²,

Heid³

et al. 2018

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…The majority of patients with psoriatic arthritis also have psoriasis, with skin disease typically preceding the manifestation of joint disease [1,2,4,5]. Psoriatic arthritis affects an estimated 0.3-1.0 % of the general population [6] (and approximately 20-30 % of patients with psoriasis [5]), and can result in significant functional disability and impaired health-related quality of life (HR-QoL) [2,6].…”

Section: Introductionmentioning

confidence: 99%

Secukinumab: A Review in Psoriatic Arthritis

Shirley

Scott

2016

Drugs

View full text Add to dashboard Cite

Secukinumab (Cosentyx(®)) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. It is the first-in-class anti-IL-17 agent, initially approved for the treatment of plaque psoriasis, and more recently for the treatment of ankylosing spondylitis and psoriatic arthritis. This article reviews the therapeutic efficacy of subcutaneous secukinumab in the treatment of psoriatic arthritis, as well as discussing the tolerability and pharmacological properties of the drug. Phase III clinical trial data demonstrated that, compared with placebo, subcutaneous secukinumab was efficacious in improving the signs and symptoms of psoriatic arthritis in patients with active disease despite previous treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or disease-modifying anti-rheumatic drugs (DMARDs). In addition, secukinumab treatment was associated with significant improvements in patient-reported measures of physical functioning and health-related quality of life. Secukinumab is generally well tolerated, with the most common adverse events being mild to moderate, non-serious infections, such as upper respiratory tract infections and nasopharyngitis. In conclusion, although longer-term and comparative data are lacking, current clinical data indicate that secukinumab is efficacious and well tolerated in the treatment of psoriatic arthritis, and it thus provides a useful treatment alternative to tumour necrosis factor inhibitors and other targeted DMARDs.

show abstract

“…В связи с этим попу-лярность ЦС при лечении ПсА в последнее время стала сни-жаться из-за необходимости тщательно отслеживать воз-можность развития этих осложнений, особенно при назна-чении дозы >3 мг/кг/сут [33]. Пациенты, принимающие ЦС, также подвержены риску возникновения плоскокле-точного рака кожи.…”

Section: общие принципы лечения псаunclassified

Current views on the pharmacotherapy of psoriatic arthritis

Тарадин¹,

Ватутин²,

Antonenko³

et al. 2015

RJTAO

View full text Add to dashboard Cite

Псориатический артрит (ПсА) представляет собой хро-ническое серонегативное воспалительное заболевание сус-тавов, ассоциирующееся с кожным псориазом [1][2][3]. Диаг-ностика ПсА нередко затруднена вследствие того, что у ча-сти больных превалируют не классические признаки «ис-тинного артрита», а проявления вертебрального пораже-ния, тендинита, энтезита или дактилита. При этом, если псориатическая природа суставного процесса не диагно-стируется своевременно, то, соответственно, не предпри-нимаются адекватные мероприятия по лечению больного, что приводит к прогрессирующему поражению суставов и ранней инвалидизации.Считается, что псориазом страдает примерно от 0,3 до 4,8% населения [4,5]. Среди больных псориазом диа-пазон распространения ПcА достаточно широк: по сооб-щениям разных авторов, он варьирует от 5 до 30% [6,7]. Рандомизированный телефонный опрос 27 220 жителей США выявил, что в общей популяции встречаемость ПcА составила 0,25%, а среди больных, страдающих псориа-зом, -11% [8]. В 2009 г. в Германии проведено обследова-ние 1511 пациентов с бляшечной формой псориаза, вы-явившее наличие ПсА у 20,6% больных, при этом лишь в 3% случаев суставная патология была диагностирована впервые [9]. (methotrexate, cyclosporine, leflunomide, sulfasalazine), and also a promising group of biologicals. Particular emphasis is placed on the results of using tumor necrosis factor inhibitors (etanercept, infliximab, golimumab, certolizumab pegol, adalimumab), interleukin inhibitors (ustekinumab, brodalumab), and phosphodiesterase 4 inhibitors (apremilast).

show abstract

Psoriatic arthritis: current therapy and future approaches

Cited by 61 publications

References 46 publications

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Evaluation of Self-reported Patient Experiences: Insights from Digital Patient Communities in Psoriatic Arthritis

Secukinumab: A Review in Psoriatic Arthritis

Current views on the pharmacotherapy of psoriatic arthritis

Contact Info

Product

Resources

About